Kromek Group plc (LSE:KMK) reported a sharp turnaround in performance for the six months to 31 October 2025, moving into profitability as revenues surged. Group revenue rose to £15.0 million from £3.7 million a year earlier, while the company swung from a pre-tax loss of £5.7 million to a profit of £3.1 million, reflecting strong momentum across both its Advanced Imaging and CBRN detection businesses.
Advanced Imaging revenue climbed to £10.8 million, driven largely by milestone deliveries under last year’s enablement agreement with Siemens Healthineers. Excluding these milestone effects, underlying imaging sales still increased by 41%. CBRN revenue more than doubled to £4.3 million, supported by government demand, including a £1.7 million order under the UK Radiological Nuclear Detection Framework and a development contract with the UK Ministry of Defence.
Improved product mix and operating leverage lifted gross margins to 71.7%, while adjusted EBITDA swung to a £6.0 million profit. The result was supported by higher-margin licensing income and continued progress in automation and capacity expansion for CZT manufacturing. To support ongoing growth, Kromek also secured an expanded £6.0 million revolving credit facility alongside additional asset finance.
Management highlighted increasing demand for CZT-based photon-counting CT systems and nuclear security solutions, renewed engagement with major OEM customers such as Spectrum Dynamics and Analogic, and continued patent activity. With a healthy order book and improving operational momentum, the group said it remains confident of delivering full-year results in line with market expectations, reinforcing its position as an independent supplier in high-barrier imaging and security markets.
More about Kromek Group plc
Kromek Group plc is a UK-headquartered developer of radiation detection and bio-detection technologies serving advanced imaging and CBRN (chemical, biological, radiological and nuclear) markets. Listed on AIM, the company supplies cadmium zinc telluride (CZT)-based detector components for medical, security and industrial imaging applications, including CT and SPECT scanners, and provides compact nuclear radiation detectors and emerging biosecurity systems for homeland defence and critical infrastructure protection. It operates manufacturing facilities in the UK and the US and focuses on enabling higher-resolution imaging and enhanced protection against radiological and biological threats.
Leave a Reply